Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 118
Summary
- Conditions
- COVID 19 Pneumonia
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Care Provider, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04305106
- Collaborators
- Renmin Hospital of Wuhan University
- Ialy Moriggia Pelascini Gravedona Hospital S.p.A
- Wuhan University
- Jiangbei Union Hospital of Huazhong University of science and technology
- Shandong Provincial Chest Hospital
- Investigators
- Principal Investigator: Yihai Cao, Dr Qilu Hospital of Shandong University, Karolinska Institutet Principal Investigator: Yuguo Chen, Dr Qilu Hospital of Shandong University